1C Trusted evidence. Informed decisions. Better health.

EDITORIAL

Telemonitoring for chronic heart failure: not ready for prime time

Juan-Pablo Casas, Joey Kwong, Shah Ebrahim

Cochrane Database of Systematic Reviews 2010;(8):ED000008 https://doi.org/10.1002/14651858.ED000008

Publication date: 9 August 2010

Chronic heart failure (CHF) is a life-threatening condition that is becoming more common in most countries due to improved treatments for acute coronary syndromes[1]. In addition, with ageing of the population, the number of people at risk of developing CHF has also increased. Improving the management of CHF is a high and growing priority for cardiovascular health services.

Multi-disciplinary team management of chronic diseases has been widely advocated, initially by geriatricians for patients with multiple pathologies. This approach has now been taken up by other specialties, although evaluations of effectiveness have been mixed [2]. Unpicking the effective components of complex interventions is challenging, and although attempts have been made to do this [3], specific trials of each component are needed to draw clear inferences. Nonetheless, finding the most 'active ingredients' of team care is an attractive proposition in low-resource settings where the full package of care may be prohibitively expensive.

The Cochrane Review by Inglis and colleagues, published in Issue 8 of the Cochrane Database of Systematic Reviews, evaluates two specific components of the multi-disciplinary approach [4]: (1) structured telephone support, which is using simple telephone technology to deliver monitoring and/or self-care management; and (2) telemonitoring, which is the electronic transmission of physiological data to a healthcare team. The review found that telemonitoring had a remarkable effect on all-cause mortality, the primary outcome: a 34% reduction in the risk of death (95% confidence intervals (CI) ranging from a 19% to a 46% reduction). The effect of telephone support is less dramatic: a 12% reduction in the risk of death (which could reflect a reduction as big as 24% or an increase of 1% in mortality, P = 0.08). Both interventions reduced CHF-related hospitalizations by about 20%, suggesting that the effects on mortality were not achieved by increasing the use of hospital resources. Beneficial effects were also found in those trials reporting quality of life outcomes, costs of care, and acceptability to patients. Taken at face value these results make a strong case for embedding telephone support and telemonitoring into routine patient care, the conclusion drawn by the authors.

Poor reporting of duration of follow-up was a problem, making it hard to calculate numbers needed to treat to benefit (NNTB). NNTBs are helpful in decision-making around healthcare delivery where quantifying the resources required to achieve health gain is a major consideration. The authors state that the annual mortality from CHF ranges from 3% to 30%; for the NNTB, this means that between 14 and 140 patients would need to use telemonitoring to avoid one death in a year. It would be important to get a clearer idea as to which of these estimates is closest to the truth before considering widespread implementation of telemonitoring.

The authors conducted several pertinent analyses to assess the robustness of their findings. Firstly, they produced funnel plots that demonstrated some evidence of 'small study bias', with more positive results in the smaller trials. Secondly, they assessed the impact of including data from trials that had not been published as full papers on their results as a post-protocol change. When they included these trials, they found that the effect of telephone support reduced markedly (risk ratio 0.96, 95% CI 0.84 to 1.09). When they applied a similar approach to the analysis of telemonitoring studies, there was no change in the results.

So, how might the findings of these inconvenient analyses be handled? When funnel plots show evidence of small study bias, the search strategy should be examined for completeness, and a wider search made for unpublished findings. It is also important to consider other causes of small study bias, for example, that the smaller trials contained sicker patients that would be more likely to benefit from intervention. A standard approach for exploring causes of small study bias and dealing with them has been reported by Egger and colleagues [5], which would be valuable to follow in updates of this review.

The authors limited the inclusion of data in the meta-analyses to studies for which a full peer-reviewed publication was available as a post-protocol change. Cautious interpretation is essential when evidence has been excluded that was intended to be included at protocol stage. Further information on the outcomes of unpublished trials should be sought from abstract authors. It is not unknown for authors to attempt to 'bury' inconvenient findings in difficult-to-find journals or to fail to publish them at all. For example, one of the largest trials of the effects of cardiac rehabilitation, which found no beneficial effect, is yet to be published in a peer-reviewed journal over a decade after its completion [6].

The authors carried out a risk of bias assessment of the primary trials, but they did not use this in a sensitivity analysis comparing



the higher-quality trials with the other trials. Making decisions requires explicit judgments to be made about the quality of evidence in terms of whether further research would or would not change confidence in the estimate of intervention effect [7].

Few of the trials measured quality of life outcomes and even fewer reported on costs. Telemonitoring may give false reassurance that may in turn result in adverse events, which were not considered here. There is no qualitative evidence concerning the process of care – something that should be an integral part of modern complex interventions [8]. Despite the huge success of large, simple drug trials in cardiology, expertise in designing highquality trials of complex interventions lags behind.

The potential for such innovations to unintentionally increase health inequalities among poorer populations must be considered. The largest single trial included in this review was conducted in Argentina, indicating both the relevance and the capacity to implement these interventions in middle-income countries. India and China both expect to find technological solutions to healthcare delivery problems, and telemonitoring is an attractive option. The principles of remote management are common to a wide range of chronic diseases (e.g. hypertension, angina, diabetes), and increasing the target patient population would widen its appeal to policy-makers and patients, and probably improve cost-effectiveness.

The authors comment on the difficulties of evaluating innovative technology in the UK National Health Service (NHS). However, unlike most health systems, the UK NHS does have the National Institute for Health and Clinical Excellence (NICE), which is the mechanism for appraisal of new technologies for use in the NHS. Telemonitoring for CHF looks ready for a NICE appraisal. On the current evidence it is likely that the verdict will be "more trials needed"

Author Information

Juan-Pablo Casas¹, Joey Kwong¹, Shah Ebrahim^{1,2}

¹Cochrane Heart Group. ²Department of Epidemiology & Population Health, London School of Hygiene & Tropical Medicine, London, UK

Declarations of interest

The authors have completed the Unified Competing Interest form at www.icmje.org/coi_disclosure.pdf (available upon request) and declare (1) no receipt of payment or support in kind for any aspect of the article; (2) that two authors (JP and JK) are paid by a UK National Institute for Health Research (NIHR) grant to the Cochrane Heart Group; (3) that the authors/spouse/partner/ children have no financial relationships with entities that have an interest in the content of the article; and (4) that there are no other relationships or activities that could be perceived as having influenced, or that giving the appearance of potentially influencing, what was written in the submitted work.

References

1. Kushner FG, Smith Jr, FC, Anderson JL, Bailey SR, Blankenship JC, Green LA, et al. 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (Updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (Updating the 2005 Guideline and 2007 Focused Update). *Circulation* 2009;120:2271–2306.

2. Smith SM, Allwright S, O'Dowd T. Effectiveness of shared care across the interface between primary and specialty care in chronic disease management. *Cochrane Database of Systematic Reviews* 2007, Issue 3. Art. No.: CD004910. DOI: 10.1002/14651858.CD004910.pub2.

3. Beswick AD, Rees K, Dieppe P, Ayis S, Gooberman-Hill R, Horwood J, et al. Complex interventions to improve physical function and maintain independent living in elderly people: a systematic review and meta-analysis. *Lancet* 2008;371(9614):725– 35.

4. Inglis SC, Clark RA, Cleland JGF, McAlister F, Stewart S. Structured telephone support or telemonitoring programs for patients with chronic heart failure. *Cochrane Database of Systematic Reviews* 2010, Issue 8. Art. No.: CD007228. DOI: 10.1002/14651858.CD007228.pub3.

5. Egger M, Sterne J, Davey Smith G. Investigating and dealing with publication and other biases in metaanalysis. *BMJ* 2001;323(7304):101–5.

6. West RR, Beswick AD. Mortality, morbidity and quality of life following cardiac rehabilitation: results of multicentre randomized controlled trial. *Journal of the American College of Cardiology* 2002;39 (Suppl B):453B.

7. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al for the GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ* 2008;336:924–6.

8. Craig P, Dieppe P, Macintyre S, Michie S, Nazareth I, Petticrew M. Developing and evaluating complex interventions: the new Medical Research Council guidance. *BMJ* 2008;337:a1655.